Weight loss continued at the 36-week mark and never plateaued, which indicates that a longer trial would still see results
While this promotes weight loss, it may not activate the same neuroprotective pathways
But simply joining two drugs together, without any tailoring to the patient, could lead to legal trouble, Brunner explains
Simultaneously, semaglutide increases production of peptides like cholecystokinin (CCK) and peptide YY (PYY), both of which amplify satiety signaling and suppress ghrelin, often called the 'hunger hormone.' Research from the STEP trials demonstrated that participants on semaglutide reported significantly lower hunger scores and greater feelings of fullness compared to placebo, even at identical calorie intakes
Druce MR, Small CK, Bloom SR
The genetic test reveals predispositionsnot guaranteed medication response or absolute outcomes